NCT05629767

Tracking of Lipid Lowering Therapy in Jordan

Tracking Lipid-Lowering Therapy Over One Year in Middle Eastern Patients With ASCVD. The Jordan LLA Tracking Study

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (actual)
• Sponsor: Jordan Collaborating Cardiology Group · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The present study aims to examine the clinical practice of modifying the dose of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease (ASCVD), who have LDL-C \> 70 mg/dl despite statin treatment.

Detailed description

ASCVD is the leading cause of morbidity and mortality worldwide, in the Middle East and in Jordan. One of the major risk factors that contribute to the development and progression of ASCAD is dyslipidemia. A large number of clinical trials have reported the benefits of lowering LDL-C, in reducing the mortality rate among ASCAD patients. The 2019 ACC/AHA blood cholesterol treatment guideline to reduce atherosclerotic cardiovascular risk in adults has expanded the role of LDL-C targets and reiterated the importance of achieving an LDL-C level of 70 mg/dl or less for patients who have ASCVD. Patients on statins and other lipid-lowering therapy in Jordan have not been tracked in the past for the potential of up escalating the lipid-lowering therapy to reach the LDL-C target. The investigation will enroll patients with ASCVD who have LAL-C \>70 mg/dl on lipid-lowering therapy and follow them for 12 months to examine the treating physicians' action in up-titrating the lipid-lowering therapy dose(s) and the frequency of measuring serum lipids during the study period.

Conditions

• Dyslipidemias
• Atherosclerotic Cardiovascular Disease

Timeline

• Start date: 2022-12-11
• Primary completion: 2023-12-13
• Completion: 2024-01-02
• First posted: 2022-11-29
• Last updated: 2024-02-13

Locations

2 sites across 1 country: Jordan